Initiator Pharma screening for Phase 2a trial for IP2018 ongoing
Initiator Pharma A/S, a clinical-stage biotech company today announced that the screening of patients for the Phase 2a clinical trial with IP2018 is ongoing and, pending the Covid-19 situation, the first dosing of patients is expected shortly.Initiator Pharma A/S, a clinical-stage biotech company today announced that the screening of patients for the Phase 2a clinical trial with IP2018 is ongoing and, pending the Covid-19 situation, the first dosing of patients is expected shortly. IP2018 is a candidate drug being developed for the treatment of sexual dysfunction in patients with major